BioVie Inc logo

BioVie Inc

$ 2.49 +0.08 (+3.32%) 04:00 PM EST
P/E:
At Loss
P/B:
6.11
Market Cap:
$ 79.38M
Enterprise V:
$ 59.94M
Volume:
74.91K
Avg Vol (2M):
466.85K
Volume:
74.91K
Market Cap $:
79.38M
PE Ratio:
At Loss
Avg Vol (2-Month):
466.85K
Enterprise Value $:
59.94M
PB Ratio:
6.11
GF Score:
Year:
Embed
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download

Business Description

Description
BioVie Inc is a company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is currently focused on developing and commercializing BIV201, a novel investigational approach to the treatment of ascites due to chronic liver cirrhosis. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. The company recently acquired the assets of NeurMedix Inc including NE3107 that inhibits inflammatory activation of ERK and NFB.
Name Current Vs Industry Vs History
Cash-To-Debt 2.09
Equity-to-Asset 0.38
Debt-to-Equity 1.18
Debt-to-EBITDA -0.08
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 51.19
9-Day RSI 46.93
14-Day RSI 47.21
6-1 Month Momentum % -33.81
12-1 Month Momentum % -52.3

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.74
Quick Ratio 5.74
Cash Ratio 5.68

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -204.9
Name Current Vs Industry Vs History
ROE % -1192.29
ROA % -755.35
ROIC % -5566.62
ROC (Joel Greenblatt) % -116765.35
ROCE % -855.99

Financials (Next Earnings Date:2022-11-10 Est.)

BIVI's 30-Y Financials

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:BIVI

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
To

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Embed

Valuation Box

Year:
Embed

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -1.06
Beta 1.88
Volatility % 128.19
14-Day RSI 47.21
14-Day ATR ($) 0.327678
20-Day SMA ($) 2.59
12-1 Month Momentum % -52.3
52-Week Range ($) 1.325 - 7.6
Shares Outstanding (Mil) 30.17

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

BioVie Inc Filings

Document Form Filing Date
No Filing Data

BioVie Inc Analysis

Share your research

Headlines

See More
No news.